OS Therapies Inc. Files Amendment No. 5 to S-1 Registration Statement

TL;DR

<b>OS Therapies Inc. has filed an S-1/A amendment, signaling progress towards a public offering of its securities.</b>

AI Summary

OS Therapies Inc (OSTX) filed a Amended IPO Registration (S-1/A) with the SEC on January 25, 2024. OS Therapies Inc. filed an S-1/A (Amendment No. 5) with the SEC on January 25, 2024. The filing pertains to a registration statement under the Securities Act of 1933. The company's primary SIC Code is 2834 (Pharmaceutical Preparations). OS Therapies Inc. is incorporated in Delaware and has its principal executive offices in Rockville, Maryland. The filing indicates the proposed sale of securities to the public will commence as soon as practicable after the effective date.

Why It Matters

For investors and stakeholders tracking OS Therapies Inc, this filing contains several important signals. This amendment indicates the company is moving forward with its plans to offer securities to the public, which could provide capital for operations and growth. As a pharmaceutical preparations company, this filing is a crucial step in potentially accessing public markets for funding and increased visibility.

Risk Assessment

Risk Level: low — OS Therapies Inc shows low risk based on this filing. The filing is an S-1/A amendment, which is a procedural step in the registration process and does not contain new financial performance data or significant business updates that would alter the risk profile.

Analyst Insight

Monitor for the effectiveness of the registration statement and subsequent details regarding the public offering, including pricing and share volume.

Key Numbers

• 2024-01-25 — Filing Date (Amendment No. 5 to Form S-1 Registration Statement)
• 333-271034 — SEC File Number (Registration Statement)
• 2834 — Primary SIC Code (Pharmaceutical Preparations)

Key Players & Entities

• OS Therapies Inc. (company) — Registrant name
• 2024-01-25 (date) — Filing date
• S-1/A (filing) — Form type
• 333-271034 (filing) — SEC file number
• 2834 (industry) — Primary SIC Code
• Delaware (jurisdiction) — State of incorporation
• Rockville, Maryland (location) — Principal executive offices
• Paul A. Romness (person) — President and Chief Executive Officer

Forward-Looking Statements

• OS Therapies Inc. will complete its initial public offering within the next 6 months. (OS Therapies Inc.) — medium confidence, target: 2024-07-25

FAQ

Industry Context

OS Therapies Inc. operates within the pharmaceutical preparations industry, focusing on the development and commercialization of therapeutic products.

Regulatory Implications

The company is filing under the Securities Act of 1933, which governs the registration of securities offered to the public in the United States.

What Investors Should Do

1. Review the full S-1/A filing for detailed disclosures on the proposed securities offering.
2. Track subsequent SEC filings for updates on the registration statement's effectiveness and offering details.
3. Analyze the company's business strategy and market position in the pharmaceutical sector.

Key Dates

• 2024-01-25: Filing of Amendment No. 5 to S-1 Registration Statement — Indicates continued progress towards a public offering.

Year-Over-Year Comparison

This is Amendment No. 5 to the S-1 Registration Statement, indicating multiple prior submissions and revisions to the initial filing.

Key Financial Figures

• $5.00 — s. The initial public offering price is $5.00 per share. We have applied to list our
• $2.39 — 4. The notes will convert at a price of $2.39 per share. These shares are being regis

Filing Documents

• fs12024a5_ostherapies.htm (S-1/A) — 5708KB
• fs12024a5ex5-1_ostherapies.htm (EX-5.1) — 11KB
• fs12024a5ex23-1_ostherapies.htm (EX-23.1) — 3KB
• fs12024a5ex-fee_ostherapies.htm (EX-FILING FEES) — 52KB
• ex5-1_001.jpg (GRAPHIC) — 15KB
• ex5-1_002.jpg (GRAPHIC) — 11KB
• ex23-1_001.jpg (GRAPHIC) — 21KB
• ex23-1_002.jpg (GRAPHIC) — 92KB
• tos_logo.jpg (GRAPHIC) — 83KB
• timage_001.jpg (GRAPHIC) — 324KB
• timage_002.jpg (GRAPHIC) — 333KB
• tflowchart_001.jpg (GRAPHIC) — 315KB
• tos_logo1.jpg (GRAPHIC) — 83KB
• 0001213900-24-006228.txt (&nbsp;) — 7536KB

RISK FACTORS

RISK FACTORS &#x00a0; 13 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS &#x00a0; 49

USE OF PROCEEDS

USE OF PROCEEDS &#x00a0; 50 DIVIDEND POLICY &#x00a0; 52 CAPITALIZATION &#x00a0; 53

DILUTION

DILUTION &#x00a0; 54 MANAGEMENT&#x2019;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF&#x00a0;OPERATIONS &#x00a0; 56

BUSINESS

BUSINESS &#x00a0; 68 MANAGEMENT &#x00a0; 85

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION &#x00a0; 92

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT &#x00a0; 96 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS &#x00a0; 97

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK &#x00a0; 99 SHARES ELIGIBLE FOR FUTURE SALE &#x00a0; 104

UNDERWRITING

UNDERWRITING &#x00a0; 106 LEGAL MATTERS &#x00a0; 110 EXPERTS &#x00a0; 110 WHERE YOU CAN FIND MORE INFORMATION &#x00a0; 110 INDEX TO FINANCIAL STATEMENTS &#x00a0; F-1 i Table of Contents ABOUT THIS PROSPECTUS We have not authorized anyone to provide any information or to make any representations other than those contained in this prospectus. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the securities offered hereby and only under circumstances and in jurisdictions where it is lawful to do so. No dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus or any applicable prospectus supplement. You should assume that the information appearing in this prospectus or any prospectus supplement is accurate only as of the date on the front of those documents only, regardless of the time of delivery of this prospectus or any applicable prospectus supplement, or any sale of a security. Our business, financial condition, results of operations and prospects may have changed since those dates. We are not, and the underwriters are not, offering to sell or seeking offers to purchase these securities in any jurisdiction where the offer or sale is not permitted. We and the underwriters have not done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United&#x00a0;States. Persons outside the United&#x00a0;States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the securities as to distribution of the prospectus outside of the United&#x00a0;States. The industry and market data and certain other statistical information used throughout this prospectus are f

View Full Filing

View this S-1/A filing on SEC EDGAR